Aclarion, Inc. (NASDAQ:ACON) Sees Significant Growth in Short Interest

Aclarion, Inc. (NASDAQ:ACON) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,230,000 shares, a growth of 210.3% from the November 30th total of 396,400 shares. Currently, 11.8% of the shares of the company are sold short. Based on an average daily trading volume, of 650,100 shares, the days-to-cover ratio is currently 1.9 days.

Analyst Ratings Changes

A number of research firms recently issued reports on ACON. Ascendiant Capital Markets decreased their price objective on shares of Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a report on Wednesday, November 27th. Maxim Group restated a “hold” rating on shares of Aclarion in a research note on Friday, December 13th.

Aclarion Trading Down 0.2 %

ACON stock opened at $0.14 on Friday. Aclarion has a fifty-two week low of $0.10 and a fifty-two week high of $6.75. The stock has a fifty day moving average of $0.17 and a 200-day moving average of $0.22.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.